LONDON and BOSTON, April 29 /PRNewswire/ -- Abingworth, the
international life sciences investment group, today announced the
appointment of David Mayer as Partner. He will be based at the Company's
offices in Waltham, MA, USA and his prime responsibility will be to support
Abingworth's efforts in growth equity, which will include expansion and
acquisition financings, small buyouts and build-ups in healthcare and life
science companies. Abingworth plans to invest from 10 million pounds
Sterling ($20 million) to up to 40 million pounds ($80 million) in each of
its growth equity investments.
Mr. Mayer adds significant depth and expertise to Abingworth with more
than 12 years experience in growth equity/buyouts, of which 8 years have
been spent focused on the healthcare sector. Mr. Mayer was most recently a
Managing Partner at Thoma Cressey Equity Partners (TCEP). He was one of
five Managing Partners at TCEP, which managed more than $1.75 billion in
capital, and he opened their Boston office in 2004. He was also responsible
for expanding the areas within healthcare in which the firm now invests to
include pharmaceuticals and medical products, in addition to healthcare
services. Notable investments made during his time at TCEP include: ESP
Pharma, Inc., Jazz Pharmaceuticals, Inc., Critical Care Systems, Inc.,
Essent Healthcare, Inc. and Continuing Care RX, Inc.
"We are delighted to welcome Dave to our investment team," said Stephen
Bunting, Managing Partner of Abingworth. "He has a proven track record in
growth equity and has served on the boards of several healthcare and life
science companies. His broad network of contacts and extensive experience
will provide valuable strategic support to our investment process and to
our portfolio companies. We believe he is an excellent fit with our
organization."
David Mayer said, "I am very pleased to be joining Abingworth, one of
the pioneering investment firms in the life sciences area, and I look
forward to being able to contribute my experience to help identify and
develop growth equity opportunities for the firm."
About Abingworth
Abingworth is an international life sciences investment group active on
both sides of the Atlantic with offices in London, Menlo Park (California)
and Boston. Founded in 1973, the Company invests across all stages of
development, including early-stage, growth equity and quoted companies in
the healthcare and life sciences sectors. Abingworth has funds under
management of over $1.25 billion.
|
